

Margherita Nannini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3402541/publications.pdf>

Version: 2024-02-01

115
papers

2,513
citations

212478

28
h-index

274796

44
g-index

116
all docs

116
docs citations

116
times ranked

3461
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	3.2	18
2	Analysis of microbiome in gastrointestinal stromal tumors: Looking for different players in tumorigenesis and novel therapeutic options. <i>Cancer Science</i> , 2022, 113, 2590-2599.	1.7	4
3	Targeted therapy in SDH-deficient GIST. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110232.	1.4	16
4	The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST). <i>Cancers</i> , 2021, 13, 705.	1.7	13
5	Gene Expression Landscape of SDH-Deficient Gastrointestinal Stromal Tumors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1057.	1.0	9
6	Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. <i>ESMO Open</i> , 2021, 6, 100222.	2.0	10
7	Uterine Preservation Treatments in Sarcomas: Oncological Problems and Reproductive Results: A Systematic Review. <i>Cancers</i> , 2021, 13, 5808.	1.7	7
8	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 778461.	1.3	4
9	Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093693.	1.4	71
10	Living Donor Liver Transplantation for Imatinib-Resistant Gastrointestinal Stromal Tumor Liver Metastases: A New Therapeutic Option in Transplant Oncology. <i>Liver Transplantation</i> , 2020, 26, 1373-1374.	1.3	0
11	Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis. <i>Cancers</i> , 2020, 12, 1899.	1.7	26
12	Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. <i>Cancers</i> , 2020, 12, 2126.	1.7	44
13	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFR/SDH/RAS-P Wild-Type GIST. <i>Frontiers in Oncology</i> , 2020, 10, 504.	1.3	16
14	The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3313.	1.8	22
15	Letter to the editor concerning "Liver transplantation for metastatic wild-type gastrointestinal stromal tumor in the era of molecular targeted therapies: Report of a first case". <i>American Journal of Transplantation</i> , 2020, 20, 3701-3702.	2.6	0
16	Skull Metastasis From Uterine Leiomyosarcoma, a Rare Presentation for a Rare Tumor: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2020, 10, 869.	1.3	3
17	Genetic aberrations and molecular biology of cardiac sarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091849.	1.4	13
18	Familial adenomatous polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	2.0	11

#	ARTICLE	IF	CITATIONS
19	Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation. <i>Frontiers in Immunology</i> , 2020, 11, 851.	2.2	10
20	Primary malignant pericardial tumour in Lynch syndrome. <i>BMC Cancer</i> , 2020, 20, 191.	1.1	3
21	Complete radiological response to first-line regorafenib in a patient with abdominal relapse of <i>BRAF V600E</i> mutated GIST. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092730.	1.4	4
22	Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).. <i>Journal of Clinical Oncology</i> , 2020, 38, e23518-e23518.	0.8	0
23	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. <i>Oncolmunology</i> , 2019, 8, e1617588.	2.1	41
24	Granular cell tumor of the trachea as a rare cause of dyspnea in a young woman. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100961.	0.2	4
25	The rs17084733 variant in the <i>KIT</i> 3' UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility. <i>Epigenetics</i> , 2019, 14, 545-557.	1.3	10
26	Gain of FGF4 is a frequent event in KIT/PDGFR/SDH/RAS ^{WT} GIST. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 636-642.	1.5	22
27	Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983190.	1.4	15
28	Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFR ^T mutation in a metastatic GIST patient responding to imatinib. <i>Scientific Reports</i> , 2019, 9, 2172.	1.6	5
29	Personalized Medicine in Gastrointestinal Stromal Tumors. , 2019, , 329-337.		0
30	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. <i>Pharmacogenomics Journal</i> , 2019, 19, 390-400.	0.9	20
31	Current status of the adjuvant therapy in uterine sarcoma: A literature review. <i>World Journal of Clinical Cases</i> , 2019, 7, 1753-1763.	0.3	34
32	Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 3018-3026.	0.3	7
33	Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11032-11032.	0.8	0
34	Unusual bilateral ovarian metastases from ileal gastrointestinal stromal tumor (GIST): a case report. <i>BMC Cancer</i> , 2018, 18, 301.	1.1	6
35	Whole Exome Sequencing Uncovers Germline Variants of Cancer-Related Genes in Sporadic Pheochromocytoma. <i>International Journal of Genomics</i> , 2018, 2018, 1-9.	0.8	4
36	18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879356.	1.4	28

#	ARTICLE	IF	CITATIONS
37	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879462.	1.4	27
38	A Single-Centre Experience on the Management of Adenosarcoma: A Successful Report of an Integrated Medical and Surgical Approach. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491878247.	0.6	4
39	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. <i>International Journal of Molecular Sciences</i> , 2018, 19, 732.	1.8	29
40	Identification of an Actionable Mutation of KIT in a Case of Extraskelatal Myxoid Chondrosarcoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1855.	1.8	4
41	Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. <i>Autophagy</i> , 2017, 13, 452-463.	4.3	59
42	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017, 15, 553-562.	1.5	53
43	An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. <i>Angiogenesis</i> , 2017, 20, 139-148.	3.7	10
44	The progressive fragmentation of the KIT/PDGFR α wild-type (WT) gastrointestinal stromal tumors (GIST). <i>Journal of Translational Medicine</i> , 2017, 15, 113.	1.8	43
45	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 731-739.	1.4	20
46	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. <i>Oncotarget</i> , 2017, 8, 60036-60045.	0.8	17
47	Characterization of malignant gastrointestinal stromal tumors—a single center experience. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 1037-1045.	0.6	7
48	What is changing in the surgical treatment of gastrointestinal stromal tumors after multidisciplinary approach? A comprehensive literature's review. <i>Minerva Surgery</i> , 2017, 72, 219-236.	0.1	5
49	Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2016, 22, 519.	1.4	78
50	Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. <i>Anti-Cancer Drugs</i> , 2016, 27, 353-363.	0.7	5
51	Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-type gastrointestinal stromal tumours are not a single group yet. <i>European Journal of Cancer</i> , 2016, 58, 38-40.	1.3	0
52	Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. <i>Tumor Biology</i> , 2016, 37, 13413-13423.	0.8	19
53	Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. <i>Epigenomics</i> , 2016, 8, 1347-1366.	1.0	23
54	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. <i>Oncotarget</i> , 2016, 7, 69412-69419.	0.8	17

#	ARTICLE	IF	CITATIONS
55	SDHC methylation in gastrointestinal stromal tumors (GIST): a case report. BMC Medical Genetics, 2015, 16, 87.	2.1	22
56	An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild-type gastrointestinal stromal tumours. Histopathology, 2015, 67, 746-747.	1.6	1
57	Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis. International Journal of Molecular Sciences, 2015, 16, 15592-15608.	1.8	32
58	Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Medicine, 2015, 4, 101-103.	1.3	80
59	Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). BMC Genomics, 2015, 16, 892.	1.2	48
60	Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. European Journal of Human Genetics, 2015, 23, 817-823.	1.4	17
61	Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma. BMC Research Notes, 2015, 8, 325.	0.6	14
62	miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers. Epigenomics, 2015, 7, 1033-1049.	1.0	27
63	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genetics in Medicine, 2015, 17, 391-395.	1.1	41
64	Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFR \pm genotype evaluated by next generation sequencing (NGS). Oncotarget, 2015, 6, 42243-42257.	0.8	20
65	Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. Oncology Letters, 2014, 8, 1793-1799.	0.8	6
66	Integrated genomic study of quadruple-WT GIST (KIT/PDGFR \pm /SDH/RAS pathway wild-type GIST). BMC Cancer, 2014, 14, 685.	1.1	70
67	Novel Clinically Relevant Genes in GIST – Letter. Clinical Cancer Research, 2014, 20, 2014-2014.	3.2	0
68	Treatments for gastrointestinal stromal tumors that are resistant to standard therapies. Future Oncology, 2014, 10, 2045-2059.	1.1	10
69	Liquid biopsy in gastrointestinal stromal tumors: a novel approach. Journal of Translational Medicine, 2014, 12, 210.	1.8	17
70	Dystrophin deregulation is associated with tumor progression in KIT/PDGFR \pm mutant gastrointestinal stromal tumors. Clinical Sarcoma Research, 2014, 4, 9.	2.3	9
71	Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFR \pm wild-type GIST. European Journal of Human Genetics, 2014, 22, 32-39.	1.4	90
72	Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience. Journal of Clinical Oncology, 2014, 32, 10515-10515.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. <i>World Journal of Gastroenterology</i> , 2014, 20, 7049.	1.4	22
74	Integrate whole genomic study of KIT/PDGFR α wild-type (WT) GIST. <i>Journal of Clinical Oncology</i> , 2014, 32, 10513-10513.	0.8	0
75	Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future. <i>Histology and Histopathology</i> , 2014, 29, 167-75.	0.5	1
76	Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. <i>International Journal of Surgery Case Reports</i> , 2013, 4, 7-10.	0.2	6
77	Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. <i>Pharmacological Research</i> , 2013, 68, 1-6.	3.1	64
78	Expression of IGF-1 receptor in KIT/PDGF receptor-wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. <i>Future Oncology</i> , 2013, 9, 121-126.	1.1	30
79	An overview on molecular biology of KIT/PDGFR α wild type (WT) gastrointestinal stromal tumours (GIST). <i>Journal of Medical Genetics</i> , 2013, 50, 653-661.	1.5	78
80	Role of molecular analysis in the adjuvant treatment of gastrointestinal stromal tumours: It is time to define it. <i>World Journal of Gastroenterology</i> , 2013, 19, 2583.	1.4	2
81	Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. <i>Case Reports in Oncology</i> , 2012, 5, 651-656.	0.3	7
82	Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFR α wild-type metastatic gastrointestinal stromal tumours. <i>Anti-Cancer Drugs</i> , 2012, 23, 567-572.	0.7	16
83	Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. <i>BMC Cancer</i> , 2012, 12, 231.	1.1	44
84	Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice. <i>Targeted Oncology</i> , 2012, 7, 243-246.	1.7	5
85	Microscopic Margins of Resection Influence Primary Gastrointestinal Stromal Tumor Survival. <i>Oncology Research and Treatment</i> , 2012, 35, 645-648.	0.8	22
86	Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. <i>Oncology Letters</i> , 2012, 3, 677-681.	0.8	5
87	Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. <i>Medical Oncology</i> , 2012, 29, 144-150.	1.2	7
88	The Follow-up After Radical Surgery of Colorectal Cancer: Is it Time for a "Tailored" Strategy?. <i>Clinical Colorectal Cancer</i> , 2011, 10, 81-84.	1.0	0
89	New molecular targets beyond KIT and PDGFR α in gastrointestinal stromal tumors: present and future. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 803-815.	1.5	1
90	Three cases of bone metastases in patients with gastrointestinal stromal tumors. <i>Rare Tumors</i> , 2011, 3, 51-53.	0.3	29

#	ARTICLE	IF	CITATIONS
91	A Distinct Pediatric-type Gastrointestinal Stromal Tumor in Adults. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1750-1752.	2.1	40
92	Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense?. <i>Colorectal Disease</i> , 2011, 13, 542-548.	0.7	3
93	Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. <i>Histopathology</i> , 2011, 59, 1071-1080.	1.6	22
94	The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting. <i>Journal of Translational Medicine</i> , 2011, 9, 75.	1.8	41
95	Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. <i>Rare Tumors</i> , 2011, 3, 153-154.	0.3	18
96	Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (case reports). <i>Oncology Reports</i> , 2011, 25, 113-20.	1.2	10
97	A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. <i>Laboratory Investigation</i> , 2010, 90, 1285-1294.	1.7	77
98	Management of Patients with Gastrointestinal Stromal Tumor in Clinical Practice in Italy: A Critical "Event Tree Model" Analysis of Decision-Making Processes and Outcomes. <i>Tumori</i> , 2010, 96, 219-228.	0.6	0
99	The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). <i>Journal of Translational Medicine</i> , 2010, 8, 117.	1.8	11
100	Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. <i>Cancer Treatment Reviews</i> , 2010, 36, 63-68.	3.4	6
101	Preclinical evaluation of KIT/PDGFR and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 173.	3.5	31
102	¹¹ C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. <i>Tumori</i> , 2009, 95, 382-384.	0.6	28
103	Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). <i>Oncology Reports</i> , 2009, 21, 1359-66.	1.2	52
104	Molecular Imaging of EGFR: It's Time to Go Beyond Receptor Expression. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1195-1196.	2.8	7
105	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. <i>Annals of Oncology</i> , 2009, 20, 213-226.	0.6	37
106	Insulin-like growth factor 1 receptor expression in wild-type GISTs: A potential novel therapeutic target. <i>International Journal of Cancer</i> , 2009, 125, 2991-2994.	2.3	70
107	To widen the setting of cancer patients who could benefit from metronomic capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 189-193.	1.1	15
108	Gene expression profiling in colorectal cancer using microarray technologies: Results and perspectives. <i>Cancer Treatment Reviews</i> , 2009, 35, 201-209.	3.4	151

#	ARTICLE	IF	CITATIONS
109	Unusual Finding of Benign Abrikossoff Tumor by F-18 FDG-PET Mimicking Melanoma Recurrence. <i>Clinical Nuclear Medicine</i> , 2009, 34, 696-697.	0.7	5
110	The Response Evaluation Criteria in Solid Tumors: until when?. <i>Nuclear Medicine Communications</i> , 2009, 30, 185-187.	0.5	2
111	What oncologists need and require from nuclear medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1761-1765.	3.3	5
112	Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. <i>British Journal of Cancer</i> , 2008, 99, 1729-1734.	2.9	46
113	Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. <i>Cancer Treatment Reviews</i> , 2008, 34, 103-121.	3.4	54
114	Molecular Imaging Suggests Efficacy of Bevacizumab beyond the Second Line in Advanced Colorectal Cancer Patients. <i>Chemotherapy</i> , 2008, 54, 421-424.	0.8	13
115	Molecular imaging and targeted therapies in oncology: New concepts in treatment response assessment. A collection of cases. <i>International Journal of Oncology</i> , 1992, , .	1.4	1